GE Healthcare signs contract to design plant-based biopharmaceutical facility
The design project is the first contract for the global alliance between GE Healthcare and iBio. The alliance combines GE Healthcare's capabilities in biopharmaceutical and vaccine manufacturing technologies and process design with iBio's plant-based manufacturing platform, iBioLaunch. The manufacturing facility will be designed for the Brazil-based Bio-Manguinhos/Fiocruz, an internationally recognized manufacturer of immunobiologicals for the public health needs of the Brazilian Ministry of Health.
"Vaccines are vital in the fight against global disease and we're pleased to be working with Bio-Manguinhos/Fiocruz on this important project," Olivier Loeillot, the general manager of enterprise solutions at GE Healthcare, said. "GE Healthcare's global capabilities and industry-leading expertise in biopharmaceutical manufacturing technologies, coupled with iBio's innovative technology and experience in plant-based protein expression, provide a solid foundation for this design project. By working closely with the team at Bio-Manguinhos/Fiocruz we will together design a state-of-the-art, technologically-advanced facility that's ready to meet the vaccine needs of tomorrow."
Bio-Manguinhos currently develops and manufactures 10 vaccines, two biotherapeutics and 11 diagnostics at its facility.
"In order to accomplish our mission and to meet the Brazilian Ministry of Health's demands, we are constantly investing in innovative technologies," Artur Couto, the director of Bio-Manguinhos/Fiocruz, said. "The agreement with GE Healthcare is important because it will allow us to build a new facility based on a very innovative platform and address an important need of the Brazilian Ministry of Health."